Cambridge Trust Co. Lowers Stake in Moderna, Inc. (NASDAQ:MRNA)

Cambridge Trust Co. lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 37.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 334 shares of the company’s stock after selling 200 shares during the quarter. Cambridge Trust Co.’s holdings in Moderna were worth $33,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in MRNA. Cim Investment Management Inc. raised its position in Moderna by 4.2% in the 1st quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock worth $329,000 after purchasing an additional 86 shares during the period. Cetera Advisor Networks LLC raised its position in Moderna by 0.5% in the 4th quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock worth $3,088,000 after purchasing an additional 87 shares during the period. Ancora Advisors LLC raised its position in Moderna by 41.2% in the 1st quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after purchasing an additional 96 shares during the period. Sunbelt Securities Inc. raised its position in Moderna by 7.5% in the 1st quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock worth $211,000 after purchasing an additional 100 shares during the period. Finally, Allworth Financial LP raised its position in Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the sale, the insider now owns 9,267 shares in the company, valued at $917,896.35. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, President Stephen Hoge sold 2,388 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Shannon Thyme Klinger sold 544 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now owns 9,267 shares in the company, valued at approximately $917,896.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,954 shares of company stock worth $11,533,976. 15.70% of the stock is currently owned by company insiders.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $101.41 on Friday. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $144.43. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The company’s 50-day moving average is $100.63 and its 200 day moving average is $93.64.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business’s revenue was down 44.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.61 earnings per share. On average, analysts anticipate that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on MRNA shares. Canaccord Genuity Group lifted their target price on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. HSBC restated a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. Finally, Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.